Fig. 6

Lower Claudin5 correlates with unfavorable patient outcomes and decreased radiotherapy response. A Representative IHC staining of Claudin5 protein in collected clinical ESCC samples from non-response (n = 38) and response (n = 85) patients to radiotherapy. B IRS of Claudin5 protein in clinical ESCC samples. C Claudin5 protein expression in tumors and radiotherapy response rate in clinical ESCC samples. D, E Kaplan–Meier analyses of disease-free survival (DFS) and overall survival (OS) for collected clinical ESCC patients with high or low tumor Claudin5 expression. F, G Kaplan–Meier analyses of DFS (F) and OS (G) for ESCA patients with high or low tumor Claudin5 expression using TCGA database. The statistical difference was assessed with the unpaired nonparametric Mann–Whitney U test in B; Chi-square test in C; and the Logrank test for D, E, F and G; Error bars show the SD from three independent experiments. **p < 0.01